Skip to content

Placebo to match filgotinib

DRUG11 trials

Sponsors

Gilead Sciences, Alfasigma S.p.A.

Conditions

Ankylosing SpondylitisFistulizing Crohn's DiseaseNoninfectious UveitisPsoriatic ArthritisRheumatoid ArthritisSmall Bowel Crohn's Disease

Phase 2

Phase 3

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
CompletedNCT02873936
Gilead SciencesRheumatoid Arthritis
Start: 2016-07-27End: 2018-06-26Updated: 2021-05-13
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
CompletedNCT02886728
Gilead SciencesRheumatoid Arthritis
Start: 2016-08-08End: 2019-05-08Updated: 2021-06-01
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
CompletedNCT02889796
Gilead SciencesRheumatoid Arthritis
Start: 2016-08-30End: 2019-06-20Updated: 2021-06-09
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
CompletedNCT03025308
Alfasigma S.p.A.Rheumatoid Arthritis
Start: 2017-02-28End: 2025-05-16Updated: 2026-07-27
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
TerminatedNCT04115748
Gilead SciencesPsoriatic Arthritis
Start: 2019-12-03End: 2021-05-11Updated: 2022-05-16
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
TerminatedNCT04115839
Gilead SciencesPsoriatic Arthritis
Start: 2019-11-13End: 2021-03-18Updated: 2022-03-18
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
WithdrawnNCT04483687
Gilead SciencesAnkylosing Spondylitis
Start: 2020-12-31End: 2024-09-30Updated: 2021-01-11
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
WithdrawnNCT04483700
Gilead SciencesAnkylosing Spondylitis
Start: 2020-12-31End: 2024-06-30Updated: 2021-01-11

Related Papers

JAMA Ophthalmology2024-07-1818 citations

27 more papers not shown